12.18.25 -- The Top 10 Nations Redrawing The Outsourcing Map

Explore the advancing mass spectrometry, biophysical characterization, automated sample preparation, and high throughput analytics required to deliver medicines in a safe, compliant, and efficient manner.

Improving your ADC’s chance of clinical success requires an understanding of what potential obstacles lie ahead and what capabilities and expertise are necessary to overcome them.

By prioritizing the management of Out of Expectation (OOX) results within your CDMO laboratory, learn how you can ensure product integrity, patient safety, and unwavering regulatory compliance.

The next generation of program managers who liaise with contract manufacturers will require an expanded, adaptable skill set to thrive in an increasingly complex environment.

Controlled nucleation standardizes freezing across all vials, leading to uniform ice crystals and improved lyo cake quality. This critical step reduces variability and supports robust product scale-up.

This resource provides a clear roadmap for delivering advanced sterile injectable therapies with confidence, meeting both regulatory demands and patient needs without compromise.

A miscalculated analytical approach can be costly to develop, perform, and maintain. Many organizations also lack appropriate resources to create optimal testing methods and protocols.

BD’s Vystra™ Disposable Pen for Liraglutide 3.0 mg demonstrated comparable usability to the reference device, helping de-risk ANDA submissions through proactive human factors evaluation.

The combination product market is consistently expanding. Transitioning from traditional vial systems to needle-based combination products presents several challenges that require careful consideration.

With active pharmaceutical ingredient (API) values continuing to climb as production scales conversely drop, it is time to rethink our aseptic filling processes to minimize API loss.

See how a large-scale manufacturing process was rapidly requalified in eight months to secure a clinical-stage biologic program by mitigating geopolitical risk and maintaining supply continuity.

The following process characterization services are based on QbD principles, with an emphasis on risk and knowledge management and transforming data into the currency of product and process.

Accelerate your therapeutic antibody and complex protein development with advanced mammalian cell line platforms that move from DNA to RCB in just 10 weeks.

Uncover a resin for recombinant protein purification with a standardized protocol that streamlines workflows from lab to production, which saves time and enhances efficiency across development stages.

Witness how our end-to-end Drug Product capabilities support the full lifecycle of biologics, seamlessly integrated with their extensive drug substance network across diverse modalities.

Partner with a trusted, globally proven CDMO whose world-class, rapidly scalable facilities and unwavering commitment to quality help accelerate patient access to life-saving biologics.